Palatin Technologies Mutually Terminates License Agreement With AMAG Pharma For Vyleesi

(RTTNews) - Palatin Technologies Inc. (PTN) said it has mutually terminated the January 2017 license agreement which granted AMAG Pharmaceuticals exclusive North American rights to market Vyleesi, the first and only on demand treatment for pre-menopausal women suffering from acquired, generalized, hypoactive sexual desire disorder (HSDD), a condition affecting one in ten premenopausal women.

Under the terms of the termination agreement, Palatin would regain all North American development and commercialization rights for Vyleesi. AMAG would make a $12 million payment to Palatin at closing and a $4.3 million payment to Palatin on March 31, 2021.

Palatin noted that it would assume all Vyleesi manufacturing agreements, and AMAG would transfer all information, data, and assets related exclusively to Vyleesi, including, but not limited to, existing inventory.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More